245 results
8-K
EX-99.1
SYRE
Spyre Therapeutics Inc.
9 May 24
Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:11pm
benefits and economic value of its product candidates, the timing and results of preclinical studies and clinical trials, including the
commencement
POS AM
SYRE
Spyre Therapeutics Inc.
26 Mar 24
Prospectus update (post-effective amendment)
6:30pm
under the CVR (as defined herein); our ability to achieve the expected benefits or opportunities and related timing with respect to our acquisition … and future clinical development activities, the efficacy and safety profile of our product candidates, the potential therapeutic benefits and economic value
424B3
dr590
18 Mar 24
Prospectus supplement
4:06pm
8-K
EX-10.1
755uvslsagnvwq
18 Mar 24
Spyre Therapeutics Announces $180 Million Private Placement
8:31am
8-K
EX-10.2
uk3ilwqg
18 Mar 24
Spyre Therapeutics Announces $180 Million Private Placement
8:31am
8-K
EX-99.1
qkew ap5m9lmc0y
18 Mar 24
Spyre Therapeutics Announces $180 Million Private Placement
8:31am
POS AM
1lrxxi5
14 Mar 24
Prospectus update (post-effective amendment)
4:12pm
POS AM
7cojzom8ii7zzcg7 ne
5 Mar 24
Prospectus update (post-effective amendment)
5:15pm
8-K
EX-99.1
tfn4l 0dv
29 Feb 24
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:14pm